EDUCATIONAL PROGRAMMES: DNA DAMAGE RESPONSE (DDR) AND PARP INHIBITION IN ONCOLOGY


DDR and PARP inhibitors are complex therapeutic strategies. These educational programmes are developed by a multidisciplinary group of international clinician and scientist experts in DDR and PARP inhibition, to enable healthcare professionals around the world to increase their understanding of DDR and PARP inhibition and provide the best possible care to their patients.


The Steering Committee:

Dr. Judith Balmaña, Prof. Simon Boulton, Dr. Robert L. Coleman, Dr. Rebecca Dent, Prof. Charlie Gourley, Prof. Jonathan A. Ledermann, Prof. Sibylle Loibl, Dr. Ursula Matulonis, Dr. Yeon Hee Park, Prof. Eric Pujade-Lauraine, Dr. Violeta Serra, Dr. Neal Shore



Please click on each programme to find out more


A comprehensive resource covering PARP inhibition and DDR as therapeutic targets across multiple tumour types, including the rationale for targeting DDR, the current role of PARP inhibition in clinical practice, and the potential future application of targeting DDR.


Access this resource at: OncologyPRO PARP inhibition and DDR


This content was developed in collaboration with COR2ED and donated to ESMO OncologyPRO


Developed by international experts in DDR and PARP inhibition, this video is available to download in full or as chapters and is supported by a summary slide deck.

This video aims to improve your understanding of PARP inhibitors as the proof of concept for targeting DDR, including how they work and their clinical benefit.

Click to view and download: Video on MoA of PARP inhibitors and targeting DDR



A review paper titled Moving from PARP Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy, published in the Journal of Clinical Oncology on May 3rd 2019.


Click to access: https://ascopubs.org/doi/abs/10.1200/JCO.18.02050

Click to access: Downloadable slides covering selected highlights for your own use


Reference guides to key aspects of DDR and PARP inhibition and their role in oncology. An accompanying slide deck summarises the key highlights from the DDR and PARP inhibition BluePrints. A variety of topics are covered, including the role of DDR in oncology, synthetic lethality, use of PARP inhibition in oncology, efficacy and safety of currently approved PARP inhibitors, and the role of combination therapy with PARP inhibitors.


AstraZeneca has provided a sponsorship grant towards this independent programme